HUP0302726A2 - Eljárások rák kezelésére szolgáló epotilon analógokat tartalmazó gyógyszerkészítmények előállítására és beadására - Google Patents

Eljárások rák kezelésére szolgáló epotilon analógokat tartalmazó gyógyszerkészítmények előállítására és beadására

Info

Publication number
HUP0302726A2
HUP0302726A2 HU0302726A HUP0302726A HUP0302726A2 HU P0302726 A2 HUP0302726 A2 HU P0302726A2 HU 0302726 A HU0302726 A HU 0302726A HU P0302726 A HUP0302726 A HU P0302726A HU P0302726 A2 HUP0302726 A2 HU P0302726A2
Authority
HU
Hungary
Prior art keywords
patient
involving
treating cancer
optionally substituted
alkyl
Prior art date
Application number
HU0302726A
Other languages
English (en)
Inventor
Rebanta Bandyopadhyay
Timothy M. Malloy
Andrea Panaggio
Krishnaswamy Srinivas Raghavan
Sailesh Amital Varia
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28678063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302726(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Priority claimed from PCT/US2002/001813 external-priority patent/WO2002058700A1/en
Publication of HUP0302726A2 publication Critical patent/HUP0302726A2/hu
Publication of HUP0302726A3 publication Critical patent/HUP0302726A3/hu
Publication of HU229349B1 publication Critical patent/HU229349B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgyát epotilon analógokat tartalmazó, orális vagyintravénás infúziós alkalmazásra szolgáló gyógyszerkészítményformázása és a készítmény rákos beteg intravénás vagy oráliskezelésére szolgáló eljárás képezi. Az analógot legalább 50 térfogat%terc-butil-alkoholt vízben tartalmazó oldószerelegyben oldják, majdliofilizálják és a kapott liofilizátumot egy fiolában, vízmentesetanol és egy nemionos felületaktív anyag elegyét tartalmazó másodikfiolával együtt csomagolják. Minden lépést fénytől védett körülményekközötti hajtanak végre. Alkalmazáskor a második fiola tartamátegyesítik a liofilizált termékkel, azt így feloldva. Ezt az oldatotmegfelelő hígítószerrel az analóg koncentrációjának körülbelül 0,1mg/ml és 0,9 mg/ml közötti értékre hígítják. A betegnek az émelygés,hányás, túlérzékenység vagy gyomorirritáció meggátlására egy vagy többtovábbi terápiás szert, így H1 vagy H2 antihisztamint is beadnak. Azepotilon analógot orálisan körülbelül 0,05 mg/kg és 200mg/kg közötti,intravénásan körülbelül 1 mg/m2 és 65 mg/m2 közötti adagbanalkalmazzák. Az epotilon analógot intravénásan általában 3 hetesciklusban alkalmazzák, orálisan e ciklus előtt vagy után adják be. Másmódszer szerint az analógot egy vagy több olyan 28 napos ciklusbanalkalmazzák, amelyben az intravénás infúziót az 1., 7. és 14. napon,45 és 90 perc közötti ideig, és orálisan a 21. napon adják be. Ó
HU0302726A 2001-01-25 2002-01-22 Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer HU229349B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26422801P 2001-01-25 2001-01-25
US29000801P 2001-05-11 2001-05-11
PCT/US2002/001813 WO2002058700A1 (en) 2001-01-25 2002-01-22 Methods of administering epothilone analogs for the treatment of cancer

Publications (3)

Publication Number Publication Date
HUP0302726A2 true HUP0302726A2 (hu) 2003-11-28
HUP0302726A3 HUP0302726A3 (en) 2007-08-28
HU229349B1 HU229349B1 (en) 2013-11-28

Family

ID=28678063

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302726A HU229349B1 (en) 2001-01-25 2002-01-22 Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer

Country Status (25)

Country Link
US (1) US6670384B2 (hu)
EP (2) EP1938821B1 (hu)
KR (1) KR100851719B1 (hu)
CN (1) CN100341505C (hu)
AR (1) AR032409A1 (hu)
AT (1) ATE389401T1 (hu)
BG (1) BG66494B1 (hu)
BR (1) BRPI0206509B8 (hu)
CY (1) CY1108114T1 (hu)
CZ (1) CZ20032021A3 (hu)
DE (1) DE60225666T2 (hu)
DK (1) DK1353668T3 (hu)
EE (1) EE05301B1 (hu)
ES (1) ES2304240T3 (hu)
HK (2) HK1065946A1 (hu)
HU (1) HU229349B1 (hu)
IS (1) IS2865B (hu)
NO (1) NO20130070L (hu)
NZ (1) NZ526870A (hu)
PE (1) PE20020734A1 (hu)
PT (1) PT1353668E (hu)
SK (1) SK288098B6 (hu)
TW (1) TWI342211B (hu)
UY (1) UY27137A1 (hu)
YU (1) YU58203A (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
RU2321400C2 (ru) * 2001-03-14 2008-04-10 Бристол-Маерс Сквибб Компани Композиция аналога эпотилона в сочетании с химиотерапевтическими агентами для лечения рака
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1506203T3 (da) 2002-08-23 2007-05-14 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf
EP1663214A1 (en) * 2003-09-02 2006-06-07 Novartis AG Cancer treatment with epothilones
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
BRPI0518286A2 (pt) * 2004-11-18 2008-11-11 Bristol Myers Squibb Co microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2012170384A1 (en) 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
PL401116A1 (pl) * 2012-10-09 2014-04-14 Ryszka Florian Farmaceutyczny Zakład Naukowo-Produkcyjny Biochefa Kompozycja dodawana do płynów infuzyjnych
CN107041886A (zh) * 2016-02-06 2017-08-15 北京华昊中天生物技术有限公司 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
CN114727995B (zh) * 2020-09-02 2024-06-11 北京华昊中天生物医药股份有限公司 优替德隆的固体口服制剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE59610712D1 (de) 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
CZ303422B6 (cs) 1996-11-18 2012-09-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
WO1998038192A1 (de) 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
DE59805900D1 (de) 1997-04-18 2002-11-14 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR100669174B1 (ko) 1998-02-05 2007-01-17 노파르티스 아게 유기화합물 함유 조성물
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
EA009206B1 (ru) 1999-02-18 2007-12-28 Шеринг Акциенгезельшафт Производные 16-галогенэпотилона и их фармацевтическое использование
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
EE05301B1 (et) 2010-06-15
IS6891A (is) 2003-07-24
YU58203A (sh) 2006-08-17
IS2865B (is) 2014-02-15
EE200300320A (et) 2003-10-15
US20020169190A1 (en) 2002-11-14
BRPI0206509A8 (pt) 2017-09-19
DK1353668T3 (da) 2008-06-30
SK8562003A3 (en) 2004-07-07
PE20020734A1 (es) 2002-08-17
NO20130070L (no) 2003-09-04
UY27137A1 (es) 2002-08-30
NZ526870A (en) 2005-11-25
ES2304240T3 (es) 2008-10-01
EP1353668B1 (en) 2008-03-19
CZ20032021A3 (cs) 2004-05-12
DE60225666D1 (de) 2008-04-30
AR032409A1 (es) 2003-11-05
TWI342211B (en) 2011-05-21
CY1108114T1 (el) 2014-02-12
EP1938821A3 (en) 2009-02-18
US6670384B2 (en) 2003-12-30
BG66494B1 (bg) 2015-06-30
CN100341505C (zh) 2007-10-10
BRPI0206509B1 (pt) 2018-10-02
KR20040048874A (ko) 2004-06-10
BG108112A (bg) 2004-11-30
HK1116339A1 (en) 2008-12-19
SK288098B6 (sk) 2013-07-02
BR0206509A (pt) 2004-09-08
EP1938821B1 (en) 2016-03-30
PT1353668E (pt) 2008-06-30
ATE389401T1 (de) 2008-04-15
HK1065946A1 (en) 2005-03-11
KR100851719B1 (ko) 2008-08-11
EP1938821A2 (en) 2008-07-02
BRPI0206509B8 (pt) 2021-05-25
CN1496258A (zh) 2004-05-12
HU229349B1 (en) 2013-11-28
DE60225666T2 (de) 2009-04-16
EP1353668A1 (en) 2003-10-22
HUP0302726A3 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
HUP0302726A2 (hu) Eljárások rák kezelésére szolgáló epotilon analógokat tartalmazó gyógyszerkészítmények előállítására és beadására
US5728735A (en) Pharmaceutical composition containing R-α-lipoic acid or S-α-lipoic acid as active ingredient
JP3963976B2 (ja) クラミジア感染症治療剤
KR100851679B1 (ko) 2-(4-이소부틸페닐)프로피온산의 약학 조성물
KR100403497B1 (ko) 카바페넴 항생물질
US9238017B2 (en) Compositions with reduced hepatotoxicity
US20160000793A1 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
CN109562186A (zh) 与炎症的专门促消退介质的盐有关的组合物和方法
AU618997B2 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
EP0283139B1 (en) Anticancer compounds
US5552389A (en) Suppressory compositions against hepatic metastases of tumors
KR20090102782A (ko) 의약 조성물
WO2002064214A3 (en) Anti cancer combination of substituted pyrroles and paclitaxel
CA3032453A1 (en) Pharmaceutical formulations and their use
RU2003126170A (ru) Способы введения аналогов эпотилона при лечения рака
US3499088A (en) Stable aqueous solutions of coenzyme q with a polyoxyethylene hydrogenated castor oil and propylene glycol and process for the manufacture thereof
JP2005503323A5 (hu)
GB2252498A (en) Benzoyl carbinol and its esters, useful as inhibitors of angiogenesis
EP0006639A1 (en) Crystalline N-formimidoyl thienamycin
US3068148A (en) Cis-cinnamic acid anti-inflammatory compositions and process of treating inflammation and capillary fragility
HU194809B (en) Process for producing acyl-enamide compounds and pharmaceutical compositions containing them as active components
JPS6452721A (en) Diabetic remedy containing 7-thiapprostaglandin e1 as active ingredient
CN109320553A (zh) 用于抗病毒的新型核苷类逆转录酶抑制剂
WO2024110793A1 (en) 2-pyrone compounds and medicinal formulations containing 2-pyrone compounds for the treatment of infections and related complications due to sars virus and its variants

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: RATHONYI ZOLTAN, S.B.G. & K. SZABADALMI UEGYVI, HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU

MM4A Lapse of definitive patent protection due to non-payment of fees